A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial
Health Technology Assessment2007Vol. 11(37), pp. iii–iv, ix
Citations Over TimeTop 13% of 2007 papers
Anthony G Marson, R E Appleton, G. Baker, David Chadwick, J. Doughty, Barbara Eaton, Carrol Gamble, Ann Jacoby, Phil Shackley, Dave Smith, Catrin Tudur Smith, Alessandra Vanoli, Paula Williamson
Abstract
The evidence suggests that LTG may be a clinical and cost-effective alternative to the existing standard drug treatment, CBZ, for patients diagnosed as having partial seizures. For patients with idiopathic generalised epilepsy or difficult to classify epilepsy, VPS remains the clinically most effective drug, although TPM may be a cost-effective alternative for some patients. Three new antiepileptic drugs have recently been licensed in the UK for the treatment of epilepsy (levetiracetam, zonisamide and pregabalin), therefore these drugs should be compared in a similarly designed trial.
Related Papers
- → People with epilepsy are diagnosed most often with unspecified epilepsy, followed by focal epilepsy, generalized convulsive epilepsy, and generalized nonconvulsive epilepsy—US MarketScan data, 2010–2015(2017)13 cited
- → Evaluation of physical educators' knowledge about epilepsy(2010)21 cited
- [Occurrence of epilepsy, its types and course during the first decade of life in progeny of mothers with epilepsy--prospective study].(2001)
- → Randomized Controlled Trials for Creating Scientific Evidence of the Efficacy and Safety of Complementary and Alternative Medicine(2004)
- A compatision between one visit RCT and several visit RCT for cracked teeth.(2007)